"Stapling" scFv for multispecific biotherapeutics of superior properties

利用“钉合”技术构建scFv,用于开发具有优异性能的多特异性生物治疗药物

阅读:6
作者:Lauren E Boucher ,Elisabeth Geyer Prinslow, Michael Feldkamp ,Fang Yi ,Rupesh Nanjunda ,Sheng-Jiun Wu ,Tun Liu ,Eilyn R Lacy ,Steven Jacobs ,Natalia Kozlyuk ,Brian Del Rosario ,Bingyuan Wu ,Patricia Aquino ,Robert C Davidson ,Samantha Heyne ,Nicholas Mazzanti ,James Testa ,Michael D Diem ,Elsa Gorre ,Andrew Mahan ,Hirsh Nanda ,Harsha P Gunawardena ,Alexis Gervais ,Anthony A Armstrong ,Alexey Teplyakov ,Chichi Huang ,Adam Zwolak ,Partha Chowdhury ,Wan Cheung Cheung ,Jinquan Luo

Abstract

Single-chain fragment variable (scFv) domains play an important role in antibody-based therapeutic modalities, such as bispecifics, multispecifics and chimeric antigen receptor T cells or natural killer cells. However, scFv domains exhibit lower stability and increased risk of aggregation due to transient dissociation ("breathing") and inter-molecular reassociation of the two domains (VL and VH). We designed a novel strategy, referred to as stapling, that introduces two disulfide bonds between the scFv linker and the two variable domains to minimize scFv breathing. We named the resulting molecules stapled scFv (spFv). Stapling increased thermal stability (Tm) by an average of 10°C. In multiple scFv/spFv multispecifics, the spFv molecules display significantly improved stability, minimal aggregation and superior product quality. These spFv multispecifics retain binding affinity and functionality. Our stapling design was compatible with all antibody variable regions we evaluated and may be widely applicable to stabilize scFv molecules for designing biotherapeutics with superior biophysical properties.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。